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Busulphan (BU) is associated with neurotoxicity and risk of seizures. Hence, seizure prophylaxis is routinely
utilized during BU administration for stem cell transplantation (SCT). We collected data on the incidence of
seizures among children undergoing SCT in Italy. Fourteen pediatric transplantation centers agreed to report
unselected data on children receiving BU as part of the conditioning regimen for SCT between 2005 and 2012.
Data on 954 pediatric transplantation procedures were collected; of them, 66% of the patients received BU
orally, and the remaining 34%, i.v. All the patients received prophylaxis of seizures, according to local pro-
tocols, consisting of different schedules and drugs. A total of 13 patients (1.3%) developed seizures; of them, 3
had a history of epilepsy (or other seizure-related pre-existing condition); 3 had documented brain lesions
potentially causing seizures per se; 1 had febrile seizures, 1 severe hypo-osmolality. In the remaining 5 pa-
tients, seizures were considered not explained and, thus, potentially related to BU administration. The inci-
dence of seizures in children receiving BU-containing regimen was very low (1.3%); furthermore, most of
them had at least 1deither pre-existing or concurrentdassociated risk factor for seizures.
 2014 American Society for Blood and Marrow Transplantation.edgments on page 284.
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13.10.028INTRODUCTION
Busulphan (BU) is an alkylating agent, employed for over
30 years in a variety of conditioning regimens for stem cell
transplantation (SCT) as an alternative to total body irradia-
tion (TBI). Initially introduced as a palliative treatment for
chronic myeloid leukemia in adults [1], it was then used as a
myeloablative drug in association with cyclophosphamide
[2]. BU was rapidly recognized as an effective conditioning
regimen for a variety of malignant and nonmalignant he-
matologic diseases, providing a good alternative to TBI when
it was administered at myeloablative dose (16 mg/kg) [3].
Table 1
List of Drugs Used, in Decreasing Order, for Prophylaxis of Seizures in Chil-
dren Receiving Busulphan-containing Regimens for Stem Cell
Transplantation
Drug (Route of Administration) Schedule
Carbamazepine (orally) 10-15 mg/kg/d
Clonazepam (orally) .1-.2/mg/kg/d
Valproate (orally) 10-20 mg/kg/d
Phenobarbital (orally) 3 mg/kg/d
Dintoine (orally) 5-10 mg/kg/d
Lorazepam (intravenously) .03-.06 mg/kg/d
Lorazepam (orally) .02-.05 (max. 2 mg) every 6 h,
30 min. before BU administration
Levetiracetam (orally) 20 mg/kg/d
Midazolam (intravenously) .05 mg/kg/d
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and ﬂudarabine, in the so-called reduced-intensity condi-
tioning regimens in adults and children at a dosage of 3.2 or
6.4 mg/kg [4].
A limited degree of plasma protein binding allows BU, un-
like other lipophilic alkylating agents such as melphalan, to
easily cross the blood-brain barrier, thus achieving levels in
cerebrospinal ﬂuid that are similar to those in plasma [5,6].
Neurotoxicity was associated with BU in animals [7] and in
humans, also favored by an altered blood-brain barrier [8]. The
incidenceofneurotoxicityafterBU-basedconditioning therapy
is reported up to 10% in adults [9], and approximately 7% in
children [10]. Vassal et al. reported that higher doses (600mg/
m2 or 16mg/kg)were associatedwith an increased probability
of neurotoxic manifestations [5]. Generalized seizures are the
main manifestation of BU neurotoxicity. They are more
frequent in older patients and appear to be dose dependent,
both in children and adults [6,10,11]. In adults, seizures typi-
cally occur in the third or fourth day of BU administration,
probably as a result of drug accumulation [6,8,12]. Even
without overt seizure activity, electroencephalogram abnor-
malities can occur in up to 60% of patients [11,13,14].
Various antiepileptic drugs (AEDs) have been used for
seizure prophylaxis, including phenobarbital sodium, benzo-
diazepines (clonazepam, lorazepam), and phenytoin [15-19].
It is worth mentioning that between .5% and 1% of chil-
dren in the general population experience a nonrecurrent,
single, unprovoked convulsive episode [20]. Considering
both the potential pharmacokinetic drug interactions be-
tween AEDs and BU [21] and the effective risk of BU-related
seizures, we decided to re-evaluate the current standard
practice of using of AEDs for seizure prophylaxis in patients
receiving BU before hematopoietic SCT [22]. With the aim to
evaluate the incidence of seizures in children treated with
BU, we performed a retrospective analysis among the pedi-
atric hematology-oncology centers of the Associazione Ital-
iana Ematologia Oncologia Pediatrica.MATERIALS AND METHODS
All of the Associazione Italiana Ematologia Oncologia Pediatrica
(www.aieop.org) centers were invited to participate in a retrospective data
collection on all children receiving BU as part of their conditioning regimen
for SCT between 2005 and 2012.
Data on route of administration, drug monitoring, seizure-speciﬁc risks
factors, neurological associated conditions, seizure prophylaxis, and occur-
rence of seizures were collected on a speciﬁc form and pooled.
Only seizures occurring during or soon after (up to 2 days) last BU
administration were considered to be potentially related [15].RESULTS
A total of 954 transplantations performed in pediatric
patients were reported by the 14 participating centers. In 637
(66%) of them, BU was administered orally, whereas in the
remaining cases BU was given i.v.. All patients received pro-
phylaxis of seizures according to the local policies (Table 1).
Seizures were reported in a total of 13 patients (1.8%), 8
males and 5 females, with amedian age of 9 years. The source
for stemcellswas autologous in 5 patients and allogeneic in 8.
BU had been administered orally in 7 children and i.v. in 6.
Of the 13 reported episodes, only 5 occurred within the
time interval during which BU is expected to be present in
the peripheral blood, ie, on days -6 (n ¼ 2), 5, 3, 1. The
remaining episodes of seizures were observed between
day þ1 and day þ86 from transplantation (Table 2).
Of the 13 patients who developed seizures, 3 had a history
of epilepsy (or other seizure-related pre-existing condition);1 had febrile seizures; 3 had a brain lesion documented by
MRI, considered by the attending physicians as a possible
cause for seizures; 1 developed seizures during documented
severe plasma hypo-osmolality, in the presence of carba-
mazepine plasma levels exceeding the therapeutic range
(22 mg/L; upper normal limit 10 mg/L). Thus, only in the
remaining 5 patients the seizures were considered fully un-
explained by any concurrent factor, and thus most likely
related to BU administration (Table 2).DISCUSSION
Acute symptomatic seizures are seizures occurring at the
time of a systemic damage or in close temporal association
with a documented brain damage [23]. The risk of experi-
encing an acute symptomatic seizure is 3.6% in an 80-year
lifespan [24]. The frequency of BU-related seizures is re-
ported in the literature in the range of 10% in the absence of
speciﬁc prophylaxis [5,8,15]. This supported the develop-
ment of anticonvulsant prophylaxis as a standard of care also
in pediatrics [25]. Yet, this recommendation remains based
on a few old studies, mainly retrospective, with very limited
number of patients. Subsequent modiﬁcations in the trans-
plantation regimens, supportive care, and monitoring stra-
tegies are, thus, not taken into account.
In the present study of a large pediatric cohort of 954
transplantations, inwhich all patients received a prophylaxis,
(almost invariably orally, with carbamazepine accounting for
over one third of the cases, and clonazepam, valproate,
phenobarbital and dintoine in about 100 cases) the frequency
of seizures was 1.3%. This ﬁnding of such a low incidence of
seizures might be considered to lend some support to the
continuous use of the prophylaxis. Yet, many concerns have
been raised about the real utility of prophylaxis [26,27]. Some
authors deﬁne this persistent recommendation as “an
example of an outdated clinical practice that persist despite a
paucity of good quality supporting medical evidence [22].”
Furthermore, the use of different regimens of prophylaxis,
with different drugs and different mechanisms of action [15]
as observed also in our study, without any drug monitoring
conﬁrming the achievement of effective drug levels, or even
by using drugswhich are expected to become therapeutic in a
longer time interval, might simply represent an additional
variable in the peritransplant phase. Furthermore, in the
absence of any prophylaxis, a comparably low incidence
(1.8%) of seizures was observed in an old report of a small
series of 57 children [10], whereas no seizures at all were
observed in a large series of 344 adults, leading the authors to
challenge theneed for prophylaxis [22]. The current studyof a
large series of children shows a frequency of seizures com-
parable to that observed in untreated adults and children.
Table 2
Main Features of Thirteen Children Who Developed Seizures during SCT during or after a Busulphan-containing Preparative egimen
Case
No.
Gender/
Age, yr
Stem Cells
Source
BU
Route
Day of Onset
and
Seizure Type
EEG Prophylaxis and Notes
Likely Busulphan-Related
1 F/1.3 UCB Oral 6; repeated
episodes of
ocular deviation
Irritative Lorazepam i.v.
since 24 h before BU; previous seizures; brain CT scan: left hypoplasia, scattered
calciﬁcations; possible ischemic origin.
2 M/13 ALLO Oral 6; generalized Normal Carbamazepine since 5 days before BU; hyponatremia (122 mEq/L); on therapy with
carbamazepine, plasma levels exceeding therapeutic range (22 mg/L; range, 4 to 10).
3 M/16 Autologous Oral 5; generalized Normal
(on
day -2)
Partial complex epilepsy, arachnoid cyst, on antiepileptic therapy
4 M/19 Autologous Oral 3; myoclonus Bilateral
spikes
Lorazepam i.v. since 24 h before BU
5 M/5.7 Autologous Oral 1; partial
seizure evolving
to generalized
seizure
Irritative Carbamazepine since 24 h before BU. Normal MRI
Case Gender/
Age, yr
Stem Cells
Source
BU
Route
Seizure Type EEG Notes
Unlikely to be Busulphan-Related
6 M/5 Autologous i.v. þ1; generalized Phenobarbital since 24 h before BU.
7 M/16 ALLO i.v. þ1; generalized Irritative Epilepsy, on therapy with levetiracetam; clinical picture suggestive for PRES
8 F/13 MRD i.v. þ1; generalized NP Dintoine since 24 h before BU.
MRI: aspeciﬁc lesions
9 M/6 AUTO Oral þ10;
generalized
Dintoine since 24 h before BU.
10 F/9 MRD i.v. þ13;
generalized
Irritative Dintoine since 24 h before BU.
Previous encephalopathy; normal CT
11 F/6 PMRD i.v. þ15;
generalized
Irritative Dintoine since 24 h before BU
12 F/9 MRD i.v. þ2, þ37;
generalized
Irritative;
frontal
foci
Dintoine since 24 h before BU;
MRI cortical-subcortical alterations, hyperintense on FLAIR
13 M/11 MRD oral þ86;
generalized
Dintoine since 24 h before BU.
MRI: frontal nodal lesion (1 cm.), perilesional edema;
EEG, electroencephalogram; ALLO, allogeneic; UCB, umbilical cord blood; MRD; matched related donor; PMRD, partially matched related donor; CT, computed
tomography; MRI, magnetic resonance imaging; PRES, Posterior Reversible Encephalopathy Syndrome; FLAIR, ﬂuid attenuated inversion recovery.
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ported to have developed seizures, which, at ﬁrst evaluation,
could have been considered as BU related. Yet, at a careful
revision, themajorityof themshowedconcurrentorassociated
factors, which could, per se, make those children at risk for
seizures. In particular, 2 of them had a history of epilepsy and
wereonantiepileptic therapy (notprophylaxis),1 hadprevious
seizures with evident brain abnormalities at computed to-
mography scan, and another had febrile seizures; a ﬁfth child
developed seizuresduring inappropriate antidiuretichormone
secretion, documented by concurrent severe hyponatremia,
associated with, or possibly related to, the concurrent high
plasma levels of carbamazepine; these event may be consid-
ered to be potentially related [28]. Three additional patients
had either a history of undeﬁned encephalopathy or gross
abnormalities at magnetic resonance imaging, which in 1 case
had justiﬁed antiepileptic therapywith phenobarbital. Thus, of
the total 13, only in 5 patients the seizures were ﬁnally
considered as really unexpected. They are either males or fe-
males, ages between 5 and 19 years, undergoing autologous
(n ¼ 3) or allogeneic (n ¼ 2) transplantations. Based on this
ﬁnding, the proportion of patients who developed BU-related,
otherwise unexplained seizures might be as low as .75%.
Another open issue, ie, potential interference with BU
pharmacokinetic [21], could also be worth investigation, but
this fell outside the scopes of this retrospective survey.
In conclusion, in the present large series of children, the
proportion of children exposed to BU-containing regimen for
SCT while receiving speciﬁc prophylaxis who develop BU-related seizures appears to be very low, in the range of less
than 1%. Furthermore, anticonvulsants, as most drugs, may
have side effects and can alter the pharmacokinetic of other
drugs used during SCT [29,30]. Yet, whether children can be
given BU without prophylaxis is a question, which cannot be
answered with the present data. A prospective study on this
issue appears warranted.
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Hematopoietic stem cell transplantation (HSCT) recipients are at risk for varicella-zoster virus (VZV) reac-
tivation. Vaccination may help restore VZV immunity; however, the available live attenuated VZV vaccine
(Zostavax) is contraindicated in immunocompromised hosts. We report our experience with using a single
dose of VZV vaccine in 110 adult autologous and allogeneic HSCT recipients who were about 2 years after
transplantation, free of graft-versus-host disease, and not receiving immunosuppression. One hundred eight
vaccine recipients (98.2%) had no clinically apparent adverse events with a median follow-up period of
9.5 months (interquartile range, 6 to 16; range, 2 to 28). Two vaccine recipients (1.8%) developed a skin rash
(one zoster-like rash with associated pain, one varicella-like) within 42 days post-vaccination that resolved
with antiviral therapy. We could not conﬁrm if these rashes were due to vaccine (Oka) or wild-type VZV. No
other possible cases of VZV reactivation have occurred with about 1178 months of follow-up. Live attenuated
zoster vaccine appears generally safe in this population when vaccinated as noted; the overall vaccination risk
needs to be weighed against the risk of wild-type VZV disease in this high-risk population.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) recipients
are at increased risk for varicella-zoster virus (VZV) reac-
tivation. VZV disease after HSCT varies depending on type of
transplantation (autologous versus allogeneic) but is reported
to be as high as 30% to 53%; the highest risk has been reported
to occur during the ﬁrst year after transplantation andmay be
associated with visceral dissemination [1-8]. Antiviral pro-
phylaxis has been shown to prevent VZV reactivation;
